Financials data is unavailable for this security.
View more
Year on year PharmaSGP Holding SE grew revenues 17.80% from 85.82m to 101.10m. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 37.17% net income growth from 11.95m to 16.40m.
| Gross margin | 90.91% |
|---|---|
| Net profit margin | 16.59% |
| Operating margin | 23.73% |
| Return on assets | 13.64% |
|---|---|
| Return on equity | 56.49% |
| Return on investment | 18.34% |
More ▼
Cash flow in EURView more
In 2023, PharmaSGP Holding SE increased its cash reserves by 24.89%, or 8.12m. The company earned 26.64m from its operations for a Cash Flow Margin of 26.35%. In addition the company used 866.00k on investing activities and also paid 17.65m in financing cash flows.
| Cash flow per share | 2.30 |
|---|---|
| Price/Cash flow per share | 10.52 |
| Book value per share | 2.72 |
|---|---|
| Tangible book value per share | -2.47 |
More ▼
Balance sheet in EURView more
| Current ratio | 1.79 |
|---|---|
| Quick ratio | 1.54 |
| Total debt/total equity | 2.15 |
|---|---|
| Total debt/total capital | 0.6823 |
More ▼
Growth rates in EUR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 177.55% and 37.25%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 89.61% |
| EPS growth(5 years) | 2.18 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 28.71 |
More ▼
